Comment
doi: 10.1016/S0140-6736(10)61119-1.
PARP inhibition in BRCA-mutated breast and ovarian cancers
Affiliations
- PMID: 20656109
- DOI: 10.1016/S0140-6736(10)61119-1
Item in Clipboard
Comment
PARP inhibition in BRCA-mutated breast and ovarian cancers
Lancet.
.
No abstract available
Comment on
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.Lancet. 2010 Jul 24;376(9737):235-44. doi: 10.1016/S0140-6736(10)60892-6. Epub 2010 Jul 6. Lancet. 2010. PMID: 20609467 Clinical Trial.
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.Lancet. 2010 Jul 24;376(9737):245-51. doi: 10.1016/S0140-6736(10)60893-8. Epub 2010 Jul 6. Lancet. 2010. PMID: 20609468 Clinical Trial.
Similar articles
-
[Hereditary ovarian carcinomas: clinico-biological features and treatment].Bull Cancer. 2014 Feb;101(2):167-74. doi: 10.1684/bdc.2014.1888. Bull Cancer. 2014. PMID: 24555961 Review. French.
-
[Olaparib in ovarian cancer with BRCA mutation].Bull Cancer. 2015 Jun;102(6 Suppl 1):S82-4. doi: 10.1016/S0007-4551(15)31221-2. Bull Cancer. 2015. PMID: 26118881 Review. French.
-
BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?J BUON. 2011 Jan-Mar;16(1):184-5. J BUON. 2011. PMID: 21674877 No abstract available.
-
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15. Bull Cancer. 2015. PMID: 26384693 Review. French.
-
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.Lancet. 2010 Jul 24;376(9737):245-51. doi: 10.1016/S0140-6736(10)60893-8. Epub 2010 Jul 6. Lancet. 2010. PMID: 20609468 Clinical Trial.
Cited by
-
Epistasis in genomic and survival data of cancer patients.PLoS Comput Biol. 2017 Jul 5;13(7):e1005626. doi: 10.1371/journal.pcbi.1005626. eCollection 2017 Jul. PLoS Comput Biol. 2017. PMID: 28678836 Free PMC article.
-
BRCA1-associated RING domain-1 (BARD1) loss and GBP1 expression enhance sensitivity to DNA damage in Ewing sarcoma.Cancer Res Commun. 2022 Apr;2(4):220-232. doi: 10.1158/2767-9764.crc-21-0047. Epub 2022 Apr 20. Cancer Res Commun. 2022. PMID: 36187937 Free PMC article.
-
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition.Pharmgenomics Pers Med. 2014 Oct 3;7:307-16. doi: 10.2147/PGPM.S39765. eCollection 2014. Pharmgenomics Pers Med. 2014. PMID: 25342917 Free PMC article. Review.
-
Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models.J Clin Invest. 2021 Jun 1;131(11):e146256. doi: 10.1172/JCI146256. J Clin Invest. 2021. PMID: 34060485 Free PMC article.
-
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.Nat Genet. 2017 Oct;49(10):1476-1486. doi: 10.1038/ng.3934. Epub 2017 Aug 21. Nat Genet. 2017. PMID: 28825726 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
